Can immune markers predict success of docetaxel chemoradiotherapy?
NCT ID NCT06947668
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study looks at immune markers in tumor tissue, saliva, stool, and blood from 250 head and neck cancer patients who cannot receive cisplatin chemotherapy. Researchers want to see if these markers can predict how well patients respond to chemoradiotherapy with docetaxel. The goal is to find better ways to personalize treatment for this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- docetaxel
- What this could lead to
- If successful, this could help doctors identify which patients are most likely to benefit from docetaxel-based chemoradiotherapy, improving treatment choices.
- What could go wrong
- This is an observational biomarker study, not a treatment trial. It may not lead to direct improvements in care, and results might not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARYNX SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Universitätsklinikum Erlangen, Strahlenklinik
RECRUITINGErlangen, Bavaria, 91054, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may spare throat cancer patients from full radiation
- Aiming to spare the neck: could smarter radiation cut side effects in oral cancer?
- Less neck surgery may be just as effective for oral cancer with one affected node
- Bee product may boost health in oral cancer survivors
- Could a laser beam stop chemo mouth sores?
- Acupuncture timing may be key to preventing dry mouth in head and neck cancer patients